Why this patent and board news matters for Xeris Biopharma Holdings stock

Xeris Biopharma Holdings (XERS) has drawn fresh attention after securing a USPTO notice of allowance for a Keveyis related patent that may extend protection to 2039, alongside several board and leadership changes.

For investors, the patent development is important because it relates directly to a marketed therapy, Keveyis, and the company has indicated it plans to seek inclusion of this intellectual property in the FDA's Orange Book listing.

At the same time, Xeris Biopharma Holdings reported that it entered privately negotiated exchange agreements to retire about US$23 million of its 8.00% Convertible Senior Notes due 2028 through a mix of cash and common stock.

Corporate governance is also evolving, with Chief Executive Officer John Shannon appointed Chair of the Board from 1 July 2026. Former Chair Marla Persky will move into the role of Lead Independent Director.

The Board is expanding to eight members with the appointment of Nerissa Kreher, M.D. Her background includes senior clinical and medical roles at several biopharmaceutical companies and current service as Chief Medical Officer of Alltrna.

The recent patent progress and board changes appear alongside building momentum in Xeris Biopharma Holdings' stock, with a 30 day share price return of 38.0% and a one year total shareholder return of 74.3% suggesting sentiment has strengthened over both shorter and longer periods.

If this kind of move has you thinking about what else might be lining up catalysts, it could be worth scanning a focused list of 40 healthcare AI stocks

After a 38.0% 30 day return and one year total shareholder return of 74.3%, along with new patent protection prospects around Keveyis, is Xeris Biopharma Holdings still trading below its potential or already pricing in future growth?

Most Popular Narrative: 25.7% Undervalued

At a last close of $8.28 versus a most widely followed fair value estimate of $11.14, the current Xeris Biopharma Holdings price sits well below that narrative target, which is built on detailed assumptions about revenue growth, profitability and the cost of capital.

Analysts are assuming Xeris Biopharma Holdings's revenue will grow by 21.5% annually over the next 3 years.

Analysts assume that profit margins will increase from -13.0% today to 19.2% in 3 years time.

Want to see why this fair value sits well above today’s price? The narrative leans on expectations of faster earnings growth, rising margins and a richer future earnings multiple. Curious how those pieces fit together and what they imply for Xeris Biopharma Holdings over the next few years?

Result: Fair Value of $11.14 (UNDERVALUED)

However, the Xeris Biopharma Holdings story could change quickly if key products face tougher competition or if R&D and SG&A spending remain high relative to revenue.

Another View on Xeris Biopharma Holdings valuation

While the narrative and fair value estimate suggest Xeris Biopharma Holdings is 25.7% undervalued at $8.28 versus $11.14, the current P/E of 119x compares with a fair ratio of 35.4x and a peer average of 14.9x. That gap points to valuation risk if growth or sentiment cools.

To see how this price compares when you line it up against earnings and peers in more detail, take a closer look at the See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With mixed signals around Xeris Biopharma Holdings and its valuation, now is a good time to check the details yourself and decide how the risk reward trade off looks in your portfolio by reviewing the 3 key rewards and 1 important warning sign

Looking for more investment ideas beyond Xeris Biopharma Holdings?

If Xeris Biopharma Holdings has you thinking more broadly about opportunities, now is the time to widen your search and pressure test your next moves with fresh data backed ideas.

• Target potential bargains by scanning companies that screen as undervalued on quality and price using the 42 high quality undervalued stocks.
• Strengthen your income pillar by reviewing companies that feature in the 7 dividend fortresses and focus on sizeable yields with staying power.
• Reduce portfolio stress by checking out companies that appear in the 75 resilient stocks with low risk scores, aiming for steadier fundamentals and fewer surprises.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.